Page 4 - Forefront Analytics News Today

JMP Securities reiterated their market outperform rating on shares of Athira Pharma (NASDAQ:ATHA – Free Report) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $19.00 price target on the stock. Athira Pharma Price Performance Athira Pharma stock opened at $2.52 on Thursday. The stock’s 50 day moving average is […]

Annexon, Inc. (NASDAQ:ANNX – Free Report) – Research analysts at HC Wainwright lifted their Q2 2024 earnings estimates for Annexon in a report issued on Tuesday, May 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.22) for the quarter, up from their prior forecast of ($0.37). […]

HC Wainwright restated their buy rating on shares of Annexon (NASDAQ:ANNX – Free Report) in a report issued on Tuesday, Benzinga reports. The firm currently has a $30.00 price target on the stock. HC Wainwright also issued estimates for Annexon’s Q2 2024 earnings at ($0.22) EPS, Q3 2024 earnings at ($0.23) EPS, Q4 2024 earnings […]

Needham & Company LLC restated their buy rating on shares of Annexon (NASDAQ:ANNX – Free Report) in a research report report published on Monday morning, Benzinga reports. They currently have a $16.00 target price on the stock. Other equities research analysts also recently issued research reports about the stock. HC Wainwright reissued a buy rating […]

ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) insider Sophia Randolph sold 12,000 shares of ALX Oncology stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $15.94, for a total transaction of $191,280.00. Following the completion of the transaction, the insider now owns 330,349 […]

HC Wainwright reiterated their buy rating on shares of Jasper Therapeutics (NASDAQ:JSPR – Free Report) in a report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $65.00 price target on the stock. JSPR has been the subject of several other reports. Royal Bank of Canada began coverage on Jasper Therapeutics in a […]

Piper Sandler started coverage on shares of Zura Bio (NASDAQ:ZURA – Free Report) in a research report sent to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $26.00 price target on the stock. Separately, Oppenheimer reaffirmed an outperform rating and set a $16.00 price target (down previously from $17.00) […]

Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) has been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have updated their coverage on the […]

Zura Bio Limited (NASDAQ:ZURA – Get Free Report) Director Amit Munshi acquired 159,744 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was bought at an average cost of $3.13 per share, for a total transaction of $499,998.72. Following the completion of the transaction, the director now directly […]

Zura Bio Limited (NASDAQ:ZURA – Get Free Report) insider Michael Howell purchased 7,987 shares of the company’s stock in a transaction on Monday, April 22nd. The stock was acquired at an average price of $3.13 per share, with a total value of $24,999.31. Following the purchase, the insider now owns 7,987 shares of the company’s […]